Abstract
Oxiperomide, a new dopamine-receptor antagonist, was found to decrease dyskinesias in patients with Parkinson's disease receiving levodopa or other dopamine agonists without necessarily increasing Parkinsonian symptoms. Oxiperomide also decreased spontaneous dyskinesias in those with tics and chorea and to a less extent in those with torsion dystonia, without necessarily causing Parkinsonism. These results provide evidence that more than one population of dopamine receptors exist in the extra pyramidal system, and encourage the search for selective dopamine antagonists.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cools A. R., Van Rossum J. M. Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia. 1976 Feb 2;45(3):243–254. doi: 10.1007/BF00421135. [DOI] [PubMed] [Google Scholar]
- Costall B., Naylor R. J. Neuroleptic antagonism of dyskinetic phenomena. Eur J Pharmacol. 1975 Sep-Oct;33(2):301–312. doi: 10.1016/0014-2999(75)90174-0. [DOI] [PubMed] [Google Scholar]
- Klawans H. L., Jr, Weiner W. J. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):427–430. doi: 10.1136/jnnp.37.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tarsy D., Parkes J. D., Marsden C. D. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry. 1975 Apr;38(4):331–335. doi: 10.1136/jnnp.38.4.331. [DOI] [PMC free article] [PubMed] [Google Scholar]